Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“Reproduced from Nauck et al.(3) with permission (Diabetologia, Springer) 6 NAUCK AND MEIER”
BackgroundMethodSelf-citationThomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“C. Incretin Secretion in Type 2 Diabetes T2DM is characterized by a severely impaired or absent GIP insulinotropic effect (Nauck et al., 1986) (to be further discussed in section V) that most likely results in worsening insulin secretion.”
BackgroundMechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes
Lyssenko, V., Lupi, R., Marchetti, P., Del Guerra, S., Orho-Melander, M., Almgren, P., Sjögren, M., Ling, C., Eriksson, K.-F., Lethagen, Υ.-L., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30706 · Cited by 829
Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682
“(50), resulting in postprandial hyperglycemia, a predictor of cardiovascular complications and mortality (51).”
BackgroundFunction and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
“When investigated using isoglycemic oral and intravenous glucose challenges, such patients have almost no, or a greatly reduced, incretin effect (56).”
BackgroundEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Thorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer
Hart, P. A., Bellin, M. D., Andersen, D. K., Bradley, D., Cruz-Monserrate, Z., Forsmark, C. E., Goodarzi, M. O., Habtezion, A., Korc, M., Kudva, Y. C., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30106-6 · Cited by 551
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
The incretin system and its role in type 2 diabetes mellitus
HOLST, J., VILSBOLL, T., & DEACON, C. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 515
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Self-citationImpact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
“by bypassing absorptive processes in the gut [13, 20].”
BackgroundSelf-citationIncretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
“Thus, several studies have shown that the incretin effect, as studied by comparing the insulin or C-peptide responses to isoglycaemic oral and intravenous glucose challenges, is abolished or severely reduced in these patients [6, 7].”
BackgroundVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Glucose administered orally elicits a higher insulin secretory response than glucose infused intravenously, even at isoglycaemic concentrations, a phenomenon referred to as the ‘incretin effect’ (Figure 1) [5].”
BackgroundSelf-citationHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
“Moreover, several studies have shown reduced secretion of the incretin hormones in patients with type 2 diabetes [5, 9, 10].”
BackgroundMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
“Collectively, the incretin hormones account for 50–70% of total post-prandial insulin secretion (1, 2).”
BackgroundFarnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
Trabelsi, M.-S., Daoudi, M., Prawitt, J., Ducastel, S., Touche, V., Sayin, S. I., Perino, A., Brighton, C. A., Sebti, Y., Kluza, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms8629 · Cited by 400
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
“The incretin effect is reduced in people with type 2 diabetes (6).”
BackgroundHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Theodorakis, M. J., Carlson, O., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 396
“Contrary to reports from subjects with long-standing T2DM (47, 59), in newly diagnosed subjects late-phase GLP-1 release was augmented, concomitant with rising plasma insulin levels.”
ResultBARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
“In type 2 diabetes, the incretin effect is diminished and in parallel, post-prandial insulin secretion is deteriorating (2, 5).”
BackgroundNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Self-citationMechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery
Guidone, C., Manco, M., Valera-Mora, E., Iaconelli, A., Gniuli, D., Mari, A., Nanni, G., Castagneto, M., Calvani, M., & Mingrone, G. (2006) · Diabetes · doi:10.2337/db06-0068 · Cited by 368
“It is therefore very interesting that reduced GLP-1 response after food intake has been reported in obese subjects (30), while, contrary to what is observed in control subjects, in patients with type 2 diabetes, a reduced or absent incretin effect has been described (31,32).”
ResultCardio-Metabolic Benefits of Plant-Based Diets
Kahleova, H., Levin, S., & Barnard, N. (2017) · Nutrients · doi:10.3390/nu9080848 · Cited by 353
“In patients with type 2 diabetes, the incretin effect is diminished [69], and it seems to be influenced by diet composition.”
BackgroundVollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
“In contrast, a marked reduction of the incretin effect is characteristic of patients with type 2 diabetes (7), thereby contributing to the excess postprandial glucose excursions in such patients.”
BackgroundSelf-citationLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
“Incretin effect values were calculated by relating the difference in integrated -cell secretory responses (insulin, C-peptide, and insulin secretion rate [ISR]) between stimulation with oral and isoglycemic intravenous glucose to the response after oral glucose, which was taken as 100% (3).”
BackgroundMethodInfluentialObesity and diabetes: An update
Verma, S., & Hussain, M. E. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.06.017 · Cited by 318
Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
“In type 2 diabetes, the incretin effect is impaired (2,3), but it remains controversial to what extent the defect is caused by a reduced release of incretin hormones and whether this reduction occurs prior to the development of type 2 diabetes.”
BackgroundJørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
“The incretin effect exerted by glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which is responsible for onehalf to two-thirds of the insulin secretion during a meal in normal healthy subjects, is also severely impaired (3, 8, 34, 36, 46).”
BackgroundHansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
“For the GIP radioimmunoassay (20,21), we used the COOH-terminally directed antiserum R 65, which cross-reacts fully with murine GIP and with GIP (3-42), but not with larger forms of GIP.”
BackgroundMethodKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
Self-citationTherapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Self-citationNannipieri, M., Baldi, S., Mari, A., Colligiani, D., Guarino, D., Camastra, S., Barsotti, E., Berta, R., Moriconi, D., Bellini, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2538 · Cited by 293
“Fasting amylin, pg mL 1 83 (42) 80 (40) 38 (18) 38 (38) 36 (28) 38 (11) Fasting ghrelin, pg mL 1 32 (14) 28 (25) 24 (16) 26 (5) 25 (3) 12 (12) Fasting PP, pg mL 1b 66 (44) 72 (69) 86 (80) 64 (141) 102 (162) 154 (242) Fasting PYY, pg mL 1 75 (61) 71 (59) 119 (72) 58 (43) 63 (38) 69 (82) Fasting glucagon, pg mL 1 60 (22…”
BackgroundGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“As a result, the contribution of the incretin effect at the postprandial stimulation of insulin secretion is markedly reduced in these patients [8,175].”
BackgroundSelf-citationThomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F., & Mark, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135723 · Cited by 283
Chang, C. L. T., Lin, Y., Bartolome, A. P., Chen, Y.-C., Chiu, S.-C., & Yang, W.-C. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/378657 · Cited by 274
“an d ac tiv at es SI RT 1) [1 21 –1 25 ]”
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280
“In people with type 2 diabetes, this ability is dramatically reduced (5), as illustrated by calculation of the GIGD, which may be close to zero.”
BackgroundSchirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2006) · Gut · doi:10.1136/gut.2004.059741 · Cited by 277
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
“In people with type 2 diabetes the incretin effect is considerably diminished [3].”
BackgroundRabe, K. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01218.x · Cited by 273
“Type II diabetes is characterized by a severely reduced or absent incretin effect (Nauck et al., 1986), and these effects of roflumilast on glucose and glucagon levels, and effects on weight, may involve incretins – gastrointestinal hormones released from endocrine cells in the distal ileum and the…”
BackgroundRecent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Rachman, J., Barrow, B. A., Levy, J. C., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 269
Yousseif, A., Emmanuel, J., Karra, E., Millet, Q., Elkalaawy, M., Jenkinson, A. D., Hashemi, M., Adamo, M., Finer, N., Fiennes, A. G., et al. (2014) · Obesity Surgery · doi:10.1007/s11695-013-1066-0 · Cited by 259
“Furthermore, we studied patients without T2DM, dissecting out confounding effects of T2DM on the incretin effect [45], circulating PYY3-36 [5] and ghrelin [46].”
BackgroundPreitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D. J., Wollheim, C., Burcelin, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420518 · Cited by 256
“This insulinotropic effect, which is responsible for approximately 50% of the insulin secreted after meal absorption, becomes progressively blunted in the development of type 2 diabetes (1, 7) as a result of a decrease in the secretion of these hormones as well as a decreased response of the β cells to their action (8…”
BackgroundInfluentialCellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
Gromada, J., Holst, J. J., & Rorsman, P. (1998) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s004240050558 · Cited by 258
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
“These processes can be greatly accelerated in healthy individuals (suggesting surplus capacity) [17], but may be severely compromised in T2DM and may therefore influence postprandial glucose levels.”
BackgroundInfluentialβ Cell tone is defined by proglucagon peptides through cAMP signaling
Capozzi, M. E., Svendsen, B., Encisco, S. E., Lewandowski, S. L., Martin, M. D., Lin, H., Jaffe, J. L., Coch, R. W., Haldeman, J. M., MacDonald, P. E., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126742 · Cited by 250
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
“The original conversion factor used was 1 mU/ l insulin = 7.3 pmol/l. Adapted from Nauck et al [10] with permission.”
InfluentialThe Role of GLP-1 in the Metabolic Success of Bariatric Surgery
Hutch, C. R., & Sandoval, D. (2017) · Endocrinology · doi:10.1210/en.2017-00564 · Cited by 236
“However, in patients with T2DM (69) and, although not to”
BackgroundThe Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T., Pedersen, O., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 232
Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Self-citationGastric Inhibitory Polypeptide: the neglected incretin revisited
Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 226
Self-citationBlonde, L., & Russell‐Jones, D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
“Early studies demonstrated that the incretin effect was diminished in subjects with type 2 diabetes [21].”
BackgroundGlucagon-Like Peptide 1 Secretion by the L-Cell
Lim, G. E., & Brubaker, P. L. (2006) · Diabetes · doi:10.2337/db06-s020 · Cited by 223
“Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic”
BackgroundInfluentialImpaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
“The incretin effect is gauged by comparing insulin responses after oral ingestion of glucose and isoglycemic iv glucose infusion (IIGI), respectively (6).”
BackgroundMethodMeier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
“The diminished incretin effect in patients with type 2 diabetes was described more than 20 years ago (5), but even now the underlying causes remain elusive.”
BackgroundSelf-citationThe Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 209
“reduced to approximately 25% of the level observed in people without diabetes (87).”
Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
“The incretin effect is a phenomenon in which oral glucose (or any other way for the administration of glucose to not bypass its absorption from the gut) elicits a much higher insulin secretory response than an intravenous infusion of glucose with similar glycemic rises (14,15) or if the same amount of glucose was give…”
BackgroundMethodInfluentialSelf-citationRoles of the Gut in Glucose Homeostasis
Holst, J. J., Gribble, F., Horowitz, M., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc16-0351 · Cited by 205
“In agreement with the loss of GIGD, the incretin effect is also greatly reduced or entirely missing in patients with diabetes (9).”
BackgroundGIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207
“The incretin effect is almost completely lost in people with type 2 diabetes (T2DM) and restoration of this deficiency would therefore be of great interest (2,3).”
BackgroundAhrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 204
Update on cystic fibrosis-related diabetes
Kelly, A., & Moran, A. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.02.008 · Cited by 203
“response to an oral glucose load, with glucagon-like peptide (GLP-1) and gastric inhibitory peptide (GIP) accounting for ~90% of this response [3].”
BackgroundMetabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Brubaker, P. L., & Drucker, D. J. (2002) · Receptors and Channels · doi:10.1080/10606820213687 · Cited by 198
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationAn overview of GLP-1 agonists and recent cardiovascular outcomes trials
Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137186 · Cited by 194
Knop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., & Madsbad, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01549.x · Cited by 195
“Incretin effects were calculated by relating the difference in integrated β-cell secretory responses (AUC for insulin, C-peptide and ISR, respectively) between stimulation with OGTT and IIGI to the response after OGTT, which was taken as 100%: incretin effect (%) = 100%·(AUCOGTT − AUCIIGI)/AUCOGTT [5].”
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Knop, F. K., Vilsbøll, T., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Diabetologia · doi:10.1007/s00125-006-0566-z · Cited by 193
“In type 2 diabetes, the incretin effect has been shown to be markedly reduced or even absent [13].”
BackgroundResultIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“Data from (a, g) Nauck et al [2] (oral glucose load 50 g); (b, h) Knop et al [71] (oral glucose load 75 g); (c, i) Bagger et al [3] (oral glucose loads of 25, 75 and 125 g); (d, j) Vardarli et al [72] (oral glucose load 75 g; after placebo and vildagliptin treatment); (e, k) Vardarli et al 2014 [73] (oral glucose load…”
BackgroundMethodSelf-citationPharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187
G-protein-coupled receptors and islet function—Implications for treatment of type 2 diabetes
Winzell, M. S., & Ahrén, B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.002 · Cited by 183
“However, since GIP appears to be insufficient in stimulating insulin secretion in subjects with diabetes (Nauck et al., 1986; Vilsboll et al., 2002), GIP does not appear as a rationale treatment for the disease (Meier & Nauck, 2004).”
BackgroundThe Effect of n-3 Fatty Acids on Glucose Homeostasis and Insulin Sensitivity
FLACHS, P., ROSSMEISL, M., & KOPECKY, J. (2014) · Physiological Research · doi:10.33549/physiolres.932715 · Cited by 183
“This effect seems to be blunted in T2D subjects (Nauck et al. 1986), likely due to an impaired response to GIP and possibly also to GLP-1 (Hojberg et al. 2009), or in some cases due to a reduced GLP-1 secretion (Nauck 2011).”
Background
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.